Publications found:
253,569
Sort by:
Future Spanish Nucleic Acid Testing Market Outlook
US$ 4,720.00
Highlights Comprehensive 850-page market segmentation analysis of the Spanish NAT market. Major issues pertaining to the Spanish NAT laboratory practice, as well as key economic, regulatory, demographic, social and technological trends with significant market impact during the next ten years. An ...
February 2012
850 pages
Future UK Nucleic Acid Testing Market Outlook
US$ 4,720.00
... comparison of automated and semiautomated analyzers. Sales and market shares of leading suppliers. Over 60 specific opportunities for NAT instruments, test systems, IT and auxiliary products. Profiles of major suppliers, and emerging market entrants, including their sales, product portfolios, marketing ...
February 2012
855 pages
Future US Nucleic Acid Testing Market Outlook
US$ 6,720.00
... comparison of automated and semiautomated analyzers. Sales and market shares of leading suppliers. Over 60 specific opportunities for NAT instruments, test systems, IT and auxiliary products. Profiles of major suppliers, and emerging market entrants, including their sales, product portfolios, marketing ...
February 2012
880 pages
Emerging Tumor Markers and Companies Developing Innovative Technologies and Products
US$ 2,280.00
... Factors Lymphokines Immunohistochemical Stains. Overview of the clinical significance and market needs for both current and emerging tumor markers. Extensive listings of companies, universities and research centers developing or marketing new technologies, products, and applications. Contains 260 pages ...
February 2012
260 pages
Leading Nucleic Acid Testing Market Players
US$ 2,000.00
This 120-page report presents insightful analyses of current and emerging suppliers of NAT products, including: The 2010 Sales Product portfolio Marketing tactics Technological know-how New products in R&D Collaborative arrangements Business strategies Contains 120 pages
February 2012
120 pages
Future French Nucleic Acid Testing Market Outlook
US$ 4,720.00
Highlights Comprehensive 850-page market segmentation analysis of the French NAT market. Major issues pertaining to the French NAT laboratory practice, as well as key economic, regulatory, demographic, social and technological trends with significant market impact during the next ten years. An extensive ...
February 2012
850 pages
Future German Nucleic Acid Testing Market Outlook
US$ 4,720.00
Highlights Comprehensive 850-page market segmentation analysis of the German NAT market. Major issues pertaining to the German NAT laboratory practice, as well as key economic, regulatory, demographic, social and technological trends with significant market impact during the next ten years. An extensive ...
February 2012
850 pages
Furure Italian Nucleic Acid Testing Market Outlook
US$ 4,720.00
Highlights Comprehensive 850-page market segmentation analysis of the Italian NAT market. Major issues pertaining to the Italian NAT laboratory practice, as well as key economic, regulatory, demographic, social and technological trends with significant market impact during the next ten years. An ...
February 2012
850 pages
SUN PHARMA - Strong Base Business; Protonix Liability Not A Major Concern
US$ 140.00
We reiterate Sun Pharma as our Top Pick in the Indian pharma space after it’s higher ... to note that FY12 performance represents purely the base business with no one off upsides. Future growth ... new target price by applying a PE of 20x on FY13 base business earnings, valuing upcoming Para IVs at Rs. 25 per share ...
February 2012
6 pages
CIPLA, Withdrawing Positive Investment Alert - Structural Issues Loom Large
US$ 140.00
We withdraw our Positive Investment Alert post the dismal Q3 FY12 result that highlights Cipla’s structural issues. In addition, we believe that the supply of API of ... estimates by 18% and 12% in FY12 and FY13. We thus withdraw our Positive Investment Alert and reiterate our Market Perform rating with a target ...
February 2012
5 pages
VERTEX PHARMA - IFN-free Oral HCV Treatment – Vertex Not Out of the Race Yet!
US$ 140.00
... with G551D mutation), we see little risk to Vertex (VRTX) profitability for at least next three years ... of IL28B CC Genotype. Vertex has also accelerated the pace of developing IFN-free drugs to remain in the ... 14th Feb., 2012 on Vertex titled “IFN-free Oral HCV Treatment – Vertex Not Out of the Race Yet ...
February 2012
12 pages
Future French Microbiology Testing Market Outlook
US$ 4,720.00
Highlights Comprehensive 980-page analysis of the French microbiology testing market. Major issues pertaining to the French microbiology laboratory practice, as well as key economic, regulatory, demographic, social and technological trends with significant market impact during the next ten years. Current ...
February 2012
980 pages
Future German Microbiology Testing Market Outlook
US$ 4,720.00
Highlights Comprehensive 983-page analysis of the German microbiology testing market. Major issues pertaining to the German microbiology laboratory practice, as well as key economic, regulatory, demographic, social and technological trends with significant market impact during the next ten years. Current ...
February 2012
983 pages
Future Italian Microbiology Testing Market Outlook
US$ 4,720.00
Highlights Comprehensive 970-page analysis of the Italian microbiology testing market. Major issues pertaining to the Italian microbiology laboratory practice, as well as key economic, regulatory, demographic, social and technological trends with significant market impact during the next ten years. ...
February 2012
970 pages
Future Japanese Microbiology Testing Market Outlook
US$ 6,240.00
Highlights Comprehensive 976-page analysis of the Japanese microbiology testing market. Major issues pertaining to the Japanese microbiology laboratory practice, as well as key economic, regulatory, demographic, social and technological trends with significant market impact during the next ten years. ...
February 2012
976 pages
Future Spanish Microbiology Testing Market Outlook
US$ 4,720.00
Highlights Comprehensive 960-page analysis of the Spanish microbiology testing market. Major issues pertaining to the Spanish microbiology laboratory practice, as well as key economic, regulatory, demographic, social and technological trends with significant market impact during the next ten years. ...
February 2012
960 pages
Future UK Microbiology Testing Market Outlook
US$ 4,720.00
Highlights Comprehensive 978-page analysis of the UK microbiology testing market. Major issues pertaining to the UK microbiology laboratory practice, as well as key economic, regulatory, demographic, social and technological trends with significant market impact during the next ten years. Current ...
February 2012
978 pages
Future US Microbiology Testing Market Outlook
US$ 7,520.00
Highlights Comprehensive 1,037-page analysis of the US microbiology testing market. Major issues pertaining to the US microbiology laboratory practice, as well as key economic, regulatory, demographic, social and technological trends with significant market impact during the next ten years. Current ...
February 2012
1037 pages
DISHMAN - Result Does Not Change the Outlook
US$ 140.00
Dishman’s Q3 FY12 EBITDA was higher than our estimates owing to change in ... and Dishman Netherlands grew by 28% and 36% Y-o-Y respectively mainly due to a favorable forex. Carbogen remained flat in constant currency. In other words, this quarter does not ...
February 2012
5 pages
Growth Opportunities in Transfusion Diagnostic Testing
US$ 22,880.00
During the next ten years, the transfusion diagnostics market will undergo significant transformation, which will result from the convergence of ... than underlying technology. The changes in the marketplace will create exciting opportunities for new instruments and reagent systems, as well as auxiliary products, ...
February 2012
800 pages
The Healthcare Packaging Market 2012-2022
US$ 2,635.00
... of analyses and forecasts. Why you should buy The Healthcare Packaging Market 2012-2022 You will receive a comprehensive analysis of the ... the outline and profile of 19 major companies operating within the healthcare packaging market. Chapter 9 is a summary of the report, outlining the conclusions of the ...
February 2012
158 pages
Future French Transfusion Diagnostic Testing Market Outlook
US$ 4,320.00
... ten years. Ten-year volume and sales forecasts for 40 blood typing, grouping and infectious disease screening tests, including NAT procedures performed in French transfusion testing hospitals, and commercial laboratories. Annual placements and installed base estimates for major automated and semi-automated ...
February 2012
430 pages
Future German Transfusion Diagnostic Testing Market Outlook
US$ 4,320.00
... ten years. Ten-year volume and sales forecasts for 40 blood typing, grouping and infectious disease screening tests, including NAT procedures performed in German transfusion testing hospitals, and commercial laboratories. Annual placements and installed base estimates for major automated and semi-automated ...
February 2012
426 pages
Future Italian Transfusion Diagnostic Testing Market Outlook
US$ 4,320.00
... ten years. Ten-year volume and sales forecasts for 40 blood typing, grouping and infectious disease screening tests, including NAT procedures performed in Italian transfusion testing hospitals, and commercial laboratories. Annual placements and installed base estimates for major automated and semi-automated ...
February 2012
412 pages
Future Japanese Transfusion Diagnostic Testing Market Outlook
US$ 5,440.00
... next ten years. Ten-year volume and sales forecasts for 40 blood typing, grouping and infectious disease screening tests, including NAT procedures performed in Japanese transfusion testing hospitals, and commercial laboratories. Annual placements and installed base estimates for major automated and semi- ...
February 2012
426 pages
Future Spanish Transfusion Diagnostic Testing Market Outlook
US$ 4,320.00
... ten years. Ten-year volume and sales forecasts for 40 blood typing, grouping and infectious disease screening tests, including NAT procedures performed in Spanish transfusion testing hospitals, and commercial laboratories. Annual placements and installed base estimates for major automated and semi-automated ...
February 2012
425 pages
Future UK Transfusion Diagnostic Testing Market Outlook
US$ 4,320.00
... ten years. Ten-year volume and sales forecasts for 40 blood typing, grouping and infectious disease screening tests, including NAT procedures performed in UK transfusion testing hospitals, and commercial laboratories. Annual placements and installed base estimates for major automated and semi-automated ...
February 2012
422 pages
Future US Transfusion Diagnostic Testing Market Outlook
US$ 7,120.00
Highlights Comprehensive 460-pages market segmentation analysis of the US transfusion testing market. Major issues pertaining to the US transfusion testing practice, as well as key economic, regulatory, demographic, social and technological trends with significant market impact during the next ten years. ...
February 2012
460 pages
GILEAD - Providing the Best Antiviral Treatment Options for HIV and HCV!
US$ 140.00
Gilead (GILD) is poised for further growth, based on the FY12 ... GILD a step closer towards its goal to deliver the “best-in-class IFN-free oral pill” for HCV. Other acquisitions ... read our report released on 10th Feb., 2012 on Gilead Sciences titled “Providing the Best Antiviral Treatment Options for HIV and HCV!”
February 2012
11 pages
U.S. Market for ENT and Bronchoscopic Devices 2012
US$ 7,495.00
... biopsy forcep and TBNA needle segments. Within the U.S. ENT and Bronchoscopic Device market, companies such as Arthrocare, Boston Scientific, Karl Storz, ... report provides a comprehensive and detailed analysis of market revenues by device type, market forecasts through 2018, unit sales, average selling prices, ...
February 2012
310 pages
U.S. Market for Peripheral Vascular Devices 2012
US$ 7,495.00
... devices These devices can be used to treat either coronary arterial or peripheral arterial disease (PAD), but only those devices used for ... grow rapidly in the U.S. over the forecast period. Within the U.S. peripheral vascular market, companies such as Boston Scientific, Cordis, Cook Medical, C.R. Bard and ...
February 2012
307 pages
U.S. Market for Therapeutic Support Surfaces (TSS) 2012
US$ 7,495.00
... ulcer prevention and education on the benefits of TSS products, will help drive unit sales, rentals and the average selling price. In 2011, the bariatric beds ... the long term care and home care settings. Within the therapeutic support surfaces market, companies such as Hill-Rom, Stryker, KCI and Invacare led ...
February 2012
167 pages
Forecast Revisit 2011-2012: Consumer Health
US$ 2,000.00
... health trends behind the data. Euromonitor International’s Forecast Revisit 2011-2012: Consumer Health global briefing examines the size, growth trends and ... Supplements, Weight Management. Data coverage: market sizes (historic and forecasts), company shares, brand shares and distribution data. Why buy ...
February 2012
42 pages
Manual Wheelchair Market Shares, Strategies, and Forecasts, Worldwide, 2012 to 2018
US$ 3,700.00
WinterGreen Research announces that it has a new study on Manual Wheelchair Market Shares and Forecasts, Worldwide, 2012-2018. The 2012 study ... markets achieving 49% market share in 2011, increasing its share by several percent in the total market as a result of good marketing, execution of sales strategy, and ...
February 2012
365 pages
Indian Healthcare - New Avenues for Growth
US$ 800.00
In India, delivering an affordable healthcare to billion-plus population presents enormous challenges and opportunities for the medical community. The past decade has seen the country’s healthcare sec...
February 2012
90 pages
India Commercial Vehicle Market Analysis
US$ 800.00
Two decades ago, India opened its doors for multinational automobile companies allowing them to penetrate the market, modernize the Indian transportation picture and make it beneficial for the end-use...
February 2012
80 pages
World Market for Anti-Infectives (Antifungals, Antibacterials and Antivirals)
US$ 3,800.00
This Kalorama Information report – The World Market for Anti-Infectives - focuses on three key segments of treatment: Antifungals (Allylamines, Azoles, Polyene Macrolides, Other Antifungals) Antibacterials (Aminoglycosides, Carbapenems, Cephalosporins, Macrolides, Penicillins, Quinolones, ...
February 2012
220 pages